Skip to Main Content
Try STAT+ TODAY
Trending:
Health
Biotech
First Opinion
STAT+
The Readout

Celgene’s (new) new low & when good news goes badly

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan May 22, 2018

Reprints
The READOUT
Alex Hogan/STAT

The Readout for May 22, 2018

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Lured by a bigger payday, a medical device maker…
Lured by a bigger payday, a medical device maker sold fake plastic parts. Many were implanted…
New research casts fresh doubt on a common procedure…
New research casts fresh doubt on a common procedure that promises to increase the odds of…
From protégée to whistleblower: A former Theranos scientist says…
From protégée to whistleblower: A former Theranos scientist says Elizabeth Holmes should ‘come forward and apologize’
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories